Abstract
Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status. It is also a pioneering example of an agent that targets 'epigenetic' gene silencing, a mechanism that is exploited by cancer cells to inhibit the expression of genes that counteract the malignant phenotype.
This is a preview of subscription content, log in via an institution to check access.
References
List, A. F., Vardiman, J., Issa, J. -P. & DeWitte, T. M. Myelodysplastic syndromes. Hematology (Am. Soc. Hematol. Educ. Program) 297–317 (2004).
Hofmann, W. -K. et al. Myelodysplastic syndromes. Hematol. J. 5, 1–8 (2004).
Herman, J. G. & Baylin, S. B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042–2054 (2003).
Egger, G., Liang, G., Aparicio, A. & Jones, P. A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457–463 (2004).
FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2004/050794lbl.pdf> (2004).
Greenberg, P. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079–2088 (1997).
Silverman, L. R. et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20, 2429–2440 (2002).
Faderl, S. & Kantarjian, H. M. Novel therapies for myelodysplastic syndromes. Cancer 101, 226–241 (2004).
Anzai, H., Frost, P., & Abbruzzese, J. L. Synergistic cytotoxicity with 2′-deoxy-5-azacytidine and topotecan in vitro and in vivo. Cancer Res. 52, 2180–2185 (1992).
Kantarjian, H. et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102, 2379–2386 (2003).
List, A. et al. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 352, 549–557 (2005).
Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6–21 (2002).
Kuendgen, A. et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104, 1266–1269 (2004).
Wijermans, P. et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18, 956–962 (2000).
Claus, R. & Lubbert, M. Epigenetic targets in hematopoietic malignancies. Oncogene 22, 6489–6496 (2003).
Saiki, J. H. et al. 5-azacytidine in acute leukemia. Cancer 42, 2111–2114 (1978).
Issa, J. P. et al. Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (Decitabine) in hematopoietic malignancies. Blood 103, 1635–1640 (2004).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Issa, JP., Kantarjian, H. & Kirkpatrick, P. Azacitidine. Nat Rev Drug Discov 4, 275–276 (2005). https://doi.org/10.1038/nrd1698
Issue Date:
DOI: https://doi.org/10.1038/nrd1698
- Springer Nature Limited
This article is cited by
-
Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation
Annals of Hematology (2022)
-
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival
Clinical Epigenetics (2021)
-
Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives
Archives of Toxicology (2017)